Gonadotropin-releasing hormone receptor-targeted gene therapy of gynecologic cancers

Molecular Cancer Therapeutics

Volumn 4, Issue 2, 2005, Pages 225-231

  Gründker, Carsten ^a,b   Nia, Abdohamid Huschmand ^a   Emons, Günter ^a  

^a UNIVERSITY OF GÖTTINGEN   (Germany)

^b Department of Gynecology/Obstetrics ^*  (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

GANCICLOVIR; GONADORELIN RECEPTOR; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; THYMIDINE KINASE; TRIPTORELIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; BREAST CANCER; CANCER CELL CULTURE; CANCER INHIBITION; CONTROLLED STUDY; DRUG TARGETING; ENDOMETRIUM CANCER; FEMALE; GENE THERAPY; GENETIC TRANSCRIPTION; GYNECOLOGIC CANCER; HUMAN; HUMAN CELL; MOUSE; NONHUMAN; NUDE MOUSE; OVARY CANCER; PRIORITY JOURNAL; SIGNAL TRANSDUCTION; TUMOR VOLUME;

ANIMALS; ANTINEOPLASTIC AGENTS, HORMONAL; ANTIVIRAL AGENTS; CELL LINE, TUMOR; FEMALE; GANCICLOVIR; GENE THERAPY; GENITAL NEOPLASMS, FEMALE; HUMANS; MICE; NF-KAPPA B; PLASMIDS; PRODRUGS; RECEPTORS, LHRH; SIGNAL TRANSDUCTION; THYMIDINE KINASE; TRANSCRIPTION FACTORS; TRIPTORELIN;

EID: 14844288074     PISSN: 15357163     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (23)

1. Gründker C, Günthert AR, Westphalen S, Emons G. Biology of GnRH systems in human gynecological cancers. Eur J Endocrinol 2002;146:1-14.
2. Gründker C, Völker P, Griesinger F, et al. Antitumor effects of cytotoxic LHRH analog AN-152 on human endometrial and ovarian cancers xenografted into nude mice. Am J Obstet Gynecol 2002;187: 528-37.
3. Emons G, Müller V, Ortmann O, et al. Luteinizing hormone-releasing hormone agonist triptorelin antagonizes signal transduction and mitogenic activity of epidermal growth factor in human ovarian and endometrial cancer cell lines. Int J Oncol 1996;9:1129-37.
4. Moretti RM, Marelli MM, Dondi D, et al. Luteinizing hormone-releasing hormone agonists interfere with the stimulatory actions of epidermal growth factor in human prostatic cancer cell lines, LNCaP and DU 145. J Clin Endocrinol Metab 1996;81:3930-7.
5. Gründker C, Schulz K, Günthert AR, Emons G. Luteinizing hormone-releasing hormone induces nuclear factor κB-activation and inhibits apoptosis in ovarian cancer cells. J Clin Endocrinol Metab 2000;85:3815-20.
6. Culver KW, Ram Z, Wallbridge S, Ishii H, Oldfield EH, Blaese RM. In vivo gene transfer with retroviral vector-producer cells for treatment of experimental brain tumors. Science 1992;256:1550-2.
7. Fillat C, Carrio M, Cascante A, Sangro B. Suicide gene therapy mediated by the herpes simplex virus thymidine kinase gene/ganciclovir system: fifteen years of application. Curr Gene Ther 2003;3:13-26.
8. Emons G, Ortmann O, Schulz KD, Schally AV. Growth-inhibitory actions of analogues of luteinizing hormone releasing hormone on tumor cells. Trends Endocrinol Metab 1997;8:355-62.
9. Moolten FL. Tumor chemosensitivity conferred by inserted herpes thymidine kinase genes: paradigm for a prospective cancer control strategy. Cancer Res 1986;46:5276-81.
10. Moolten FL, Wells JM. Curability of tumors bearing herpes thymidine kinase genes transferred by retroviral vectors. J Natl Cancer Inst 1990;82:297-300.
11. Kwong YL, Chen SH, Kosai K, Finegold MJ, Woo SLC. Adenoviral-mediated suicide gene therapy for hepatic metastasis o breast cancer. Cancer Gene Ther 1996;3:339-44.
12. Qian C, Bilbao R, Bruna O, Prieto J. Induction of sensitivity to ganciclovir in human hepatocellular carcinoma cells by adenovirus-mediated gene transfer of herpes simplex virus thymidine kinase. Hepatology 1995;22:118-23.
13. Bi WL, Parysek LM, Warnick R, Stambrook PJ. In vitro evidence that metabolic cooperation is responsible foe the bystander effect observed with HSVtk retroviral gene therapy. Hum Gene Ther 1993;4:725-31.
14. Ural AU, Takebe N, Adhikari D, et al. Gene therapy for endometrial carcinoma with the herpes simplex thymidine kinase gene. Gynecol Oncol 2000;76:305-10.
15. Tong XV, Block A, Chen SH, Woo SLC, Kieback DG. Adenovirus-mediated thymidine kinase gene transduction in human epithelial ovarian cancer cell lines followed by exposure to ganciclovir. Anticancer Res 1996;16:1611-8.
16. Rosenfield ME, Wang M, Siegal GD, et al. Adenoviral-mediated delivery of herpes simplex virus thymidine kinase results in tumor reduction and prolonged survival in a SCID mouse model of human ovarian carcinoma. J Mol Med 1996;74:455-62.
17. Kunishige I, Samejima Y, Shiki Y, et al. Suicide gene therapy for human uterine adenocarcinoma cells using herpes simplex virus thymidine kinase. Gynecol Oncol 1999;72:16-25.
18. Kim J, Hwang ES, Kim JS, You EH, Lee SH. Intraperitoneal gene therapy with adenoviral-mediated p53 tumor suppressor gene for ovarian cancer model in nude mice. Cancer Gene Ther 1999;6:172-8.
19. Tong XW, Kieback DG, Ramesh R, Freeman SH. Molecular aspects of ovarian cancer. Is gene therapy the solution? Hematol Oncol Clin North Am 1999;13:109-33.
20. Wolf JK, Jenkins AD. Gene therapy for ovarian cancer (review). Int J Oncol 2002;21:461-8.
21. Robinson W, Adams J, Marrogi A, Freeman S. Vaccine therapy for ovarian cancer using herpes simplex virus-thymidine kinase (HSV-TK) suicide gene transfer technique: a phase I study. Gene Ther Mol Biol 1998;2:31-40.
22. Hasenburg A, Tong XW, Fischer A, et al. Adenovirus-mediated thymidine kinase gene therapy in combination with topotecan for patients with recurrent ovarian cancer: 2.5-year follow-up. Gynecol Oncol 2001; 83:549-54.
23. Alvarez RD, Gomez-Navarro J, Wang M, et al. Adenoviral-mediated suicide gene therapy for ovarian cancer. Mol Ther 2000;2:524-30.